- Home
- NEWP vs BMEA Comparison
NEWP vs BMEA Comparison
Compare NEWP & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- BMEA
- Stock Information
- Founded
- NEWP 1972
- BMEA 2017
- Country
- NEWP Canada
- BMEA United States
- Employees
- NEWP N/A
- BMEA N/A
- Industry
- NEWP
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- NEWP
- BMEA Health Care
- Exchange
- NEWP Nasdaq
- BMEA Nasdaq
- Market Cap
- NEWP 264.1M
- BMEA 275.6M
- IPO Year
- NEWP N/A
- BMEA 2021
- Fundamental
- Price
- NEWP $1.48
- BMEA $6.53
- Analyst Decision
- NEWP Strong Buy
- BMEA Buy
- Analyst Count
- NEWP 1
- BMEA 13
- Target Price
- NEWP $5.00
- BMEA $37.25
- AVG Volume (30 Days)
- NEWP 365.6K
- BMEA 817.8K
- Earning Date
- NEWP 11-26-2024
- BMEA 10-29-2024
- Dividend Yield
- NEWP N/A
- BMEA N/A
- EPS Growth
- NEWP N/A
- BMEA N/A
- EPS
- NEWP N/A
- BMEA N/A
- Revenue
- NEWP N/A
- BMEA N/A
- Revenue This Year
- NEWP N/A
- BMEA N/A
- Revenue Next Year
- NEWP N/A
- BMEA N/A
- P/E Ratio
- NEWP N/A
- BMEA N/A
- Revenue Growth
- NEWP N/A
- BMEA N/A
- 52 Week Low
- NEWP $0.87
- BMEA $3.61
- 52 Week High
- NEWP $2.53
- BMEA $22.74
- Technical
- Relative Strength Index (RSI)
- NEWP 38.51
- BMEA 23.64
- Support Level
- NEWP $1.47
- BMEA $8.60
- Resistance Level
- NEWP $1.78
- BMEA $9.34
- Average True Range (ATR)
- NEWP 0.12
- BMEA 0.79
- MACD
- NEWP -0.04
- BMEA -0.40
- Stochastic Oscillator
- NEWP 4.17
- BMEA 0.82
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.